1.15

0.88% +0.01

After Hours: 1.15

NanoViricides Inc (NNVC)

Overview News Price History Option Chain Discussions Forecast Stock Split

NanoViricides Inc stock is currently priced at $1.15, with a 24-hour trading volume of 13,981. It has seen a +0.88% increased in the last 24 hours and a +0.88% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $1.15 pivot point. If it approaches the $1.10 support level, significant changes may occur.

Previous Close:

$1.14

Open:

$1.14

24h Volume:

13,981

Market Cap:

$13.55M

Revenue:

Net Income/Loss:

$-9.36M

P/E Ratio:

-1.9492

EPS:

-0.59

Net Cash Flow:

$-6.20M

1W Performance:

-0.86%

1M Performance:

+0.88%

6M Performance:

-0.43%

1Y Performance:

-10.16%

1D Range:

$1.13

$1.15

52W Range:

$1.00

$2.00

NanoViricides Inc Stock (NNVC) Company Profile

Name

NanoViricides Inc

Sector

Healthcare (1200)

Industry

Biotechnology (688)

Phone

203-937-6137

Address

1 Controls Drive, Shelton, CT

Employee

Twitter

@nnvcnyse

Next Earnings Date

2024-05-13

Latest SEC Filings

NNVC's Discussions on Twitter

NanoViricides Inc Stock (NNVC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-11-15	Initiated	Midtown Partners	Strong Buy

NanoViricides Inc Stock (NNVC) Financials Data

NanoViricides Inc (NNVC) Net Income 2024

NNVC net income (TTM) was -$9.36 million for the quarter ending December 31, 2023, a -35.83% decrease year-over-year.

NanoViricides Inc (NNVC) Cash Flow 2024

NNVC recorded a free cash flow (TTM) of -$6.20 million for the quarter ending December 31, 2023, a -9.00% decrease year-over-year.

NanoViricides Inc (NNVC) Earnings per Share 2024

NNVC earnings per share (TTM) was -$0.81 for the quarter ending December 31, 2023, a -35.00% decline year-over-year.

NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of viral infections. The company is developing anti-influenza drug candidates at pre-clinical and advanced pre-clinical stage, which include two FluCide drugs, such as NV-INF-2, an oral anti-influenza drug and NV-INF-1, an injectable anti-influenza drug for H7N9, Bird Flu H5N1, and other Highly Pathogenic Influenzas; and HIVCide, an anti-human immunodeficiency virus (HIV) drug candidate that could provide functional cure for HIV/AIDS. It is also developing HerpeCide, a skin cream or gel formulation for the treatment of oral and genital herpes virus infections; and eye drops against viral infections of the external eye, as well as involved in the other research programs against Rabies virus, Ebola, and Marburg viruses. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.